AMG 925 is a dual FLT3/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia

Resistance to FLT3 inhibitors is a serious clinical issue in treating acute myelogenous leukemia (AML). AMG 925, a dual FLT3/CDK4 inhibitor, has been developed to overcome this resistance. It is hypothesized that the combined inhibition of FLT3 and CDK4 may reduce occurrence of the FLT3 resistance m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer therapeutics 2015-02, Vol.14 (2), p.375-383
Hauptverfasser:	Li, Cong, Liu, Liqin, Liang, Lingming, Xia, Zhen, Li, Zhihong, Wang, Xianghong, McGee, Lawrence R, Newhall, Katie, Sinclair, Angus, Kamb, Alexander, Wickramasinghe, Dineli, Dai, Kang
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis - drug effects Benzothiazoles - pharmacology Cell Line, Tumor Cell Proliferation - drug effects Cell Separation Clone Cells Cyclin-Dependent Kinase 4 - antagonists & inhibitors Cyclin-Dependent Kinase 4 - metabolism Drug Resistance, Neoplasm - drug effects fms-Like Tyrosine Kinase 3 - antagonists & inhibitors fms-Like Tyrosine Kinase 3 - metabolism Heterocyclic Compounds, 3-Ring - pharmacology Humans Leukemia, Myeloid, Acute - pathology Mutation - genetics Naphthyridines - pharmacology Phenylurea Compounds - pharmacology Piperazines - pharmacology Protein Kinase Inhibitors - pharmacology Pyridines - pharmacology Signal Transduction - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!